Image Place holder

Viswam S. Nair, MD, MS

Specialty: Pulmonology
Program: Thoracic Oncology

Call 1-888-MOFFITT

or call 1-888-MOFFITT


Cancer Types Treated: Lung Cancer, Mesothelioma, Pancoast Tumor, Thymoma

Dr. Viswam S. Nair MD, MS is an Assistant Professor in the Division of Pulmonary, Critical Care, and Sleep Medicine within the Department of Internal Medicine at the University of South Florida and Section Chief of Pulmonary at Moffitt Cancer Center. He specializes in the care and treatment of patients with pulmonary disease, solitary pulmonary nodules, and lung cancer in the outpatient, inpatient and high acuity units of the center. Dr. Nair was recruited from the Stanford School of Medicine in 2017 with a mission for the Moffitt pulmonary group to deliver 1) exceptional and leading edge care and 2) to develop new techniques for delivering this care through biomedical research. He currently maintains an active clinical research laboratory on-site at USF next to Moffitt Cancer Center that is involved with collaborators intramurally at Moffitt Cancer Center and USF as well as nationally with other leading academic centers. His current research interests focus on integrating clinical imaging and non-invasive biomarkers to develop new, improved diagnostic models for personalizing medicine in lung cancer patients, understanding the current limitations of “omics” and biomarker studies in clinical practice and identifying and reducing health disparities for patients at risk for lung cancer. Dr. Nair received his B.A. degree in Chemistry cum laude in 1998 from the University of Pennsylvania and his Doctor of Medicine degree from the Ohio State University College of Medicine and Public Health in 2004. He completed his residency training in internal medicine in 2007 at Santa Clara Valley Medical Center in San Jose, CA followed by his fellowship training in Pulmonary and Critical Care Medicine at Stanford Hospitals and Clinics in 2010. Following clinical fellowship, he received a master’s degree in Clinical Epidemiology from Stanford University and was Pulmonary faculty at Stanford University School of Medicine from 2012-2017 where we was a member of the Canary Center at Stanford for Cancer Early Detection, Assistant Director of the Lung Cancer Screening Program, and Co-Director of the Stanford Nodule Assessment Program. Nationally, Dr. Nair is a recognized expert and author of multiple high profile papers in biomarker research in lung cancer. He currently sits on the American Thoracic Society’s Thoracic Oncology Assembly Program and Planning Committees and has mentored multiple clinical trainees in the study and clinical care of lung cancer patients.

Education & Training

Board Certification:

  • Critical Care Medicine
  • Pulmonary Disease


  • Stanford University Medical Center - Pulmonary & Critical Care Medicine


  • Santa Clara Valley Medical Center - Internal Medicine

Medical School:

  • Ohio State University College of Medicine - MD
Participating Trials

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).


  • Park SM, Wong DJ, Ooi CC, Nesvet JC, Nair VS, Wang SX, Gambhir SS. Multigene profiling of single circulating tumor cells. Mol Cell Oncol. 2017 Mar;4(2):e1289295. Pubmedid: 28401190. Pmcid: PMC5383366.
  • Nair VS, Sundaram V, Gould MK, Desai M. Use of [(18)F]Fluoro-2-deoxy-d-glucose Positron Emission Tomographic Imaging in the National Lung Screening Trial. Chest. 2016 Sep;150(3):621-630. Pubmedid: 27179906.
  • Chaudhuri AA, Binkley MS, Rigdon J, Carter JN, Aggarwal S, Dudley SA, Qian Y, Kumar KA, Hara WY, Gensheimer M, Nair VS, Maxim PG, Shultz DB, Bush K, Trakul N, Le QT, Diehn M, Loo BW, Guo HH. Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR). Radiother Oncol. 2016 Jun;119(3):454-460. Pubmedid: 27267049.
  • Gentles AJ, Bratman SV, Lee LJ, Harris JP, Feng W, Nair RV, Shultz DB, Nair VS, Hoang CD, West RB, Plevritis SK, Alizadeh AA, Diehn M. Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Non-Small Cell Lung Cancer. J Natl Cancer Inst. 2015 Oct;107(10). Pubmedid: 26286589.
  • Carlsson A, Nair VS, Luttgen MS, Keu KV, Horng G, Vasanawala M, Kolatkar A, Jamali M, Iagaru AH, Kuschner W, Loo BW, Shrager JB, Bethel K, Hoh CK, Bazhenova L, Nieva J, Kuhn P, Gambhir SS. Circulating tumor microemboli diagnostics for patients with non-small-cell lung cancer. J Thorac Oncol. 2014 Aug;9(8):1111-1119. Pubmedid: 25157764. Pmcid: PMC4145608.